MichaelBukhaloMD

PubMed

• Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
  Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani, Zoe D Draelos, Janet DuBois, Melinda J Gooderham, Steven E Kempers, Edward Lain, ...> ;The British Journal of Dermatology. 2023 Sep 15
• 2 citations
  Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
  Matthew J Zirwas, Zoe D Draelos, Janet DuBois, Leon H Kircik, Angela Y Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, ...> ;JAMA Dermatology. 2023 Jun 1
• 3 citations
  Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
  David Rosmarin, Marta Casillas, Sherry Chen, Zach Dawson, Evangeline Pierce, Hong Zhang, Michael Bukhalo, Stacy Smith> ;Journal of Cutaneous Medicine and Surgery. 2022 Jan 28
• A seamless Phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp.
  Weiss, J.,Ulrich, M.,Bukhalo, M.,Østerdal, M. L.,Bang, B.,Hanke, C. W.> ;Br. J. Dermatol.. 2017 Jan 13
• 14 citations
  Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported exper...
  Kristina Callis Duffin, Michael Bukhalo, Margaret A Bobonich, David Shrom, Fangyi Zhao, James R. Kershner, Anne M. Gill, Beth A. Pangallo, Catherine L Shuler, Jerry Bagel> ;Medical Devices. 2016 Oct 12
• Phase 3, Open-Label, Randomized Study of the Pharmacokinetics, Efficacy and Safety of Ixekizumab Following Subcutaneous Administration Using a Prefilled Syringe or an ...
  Michael Bukhalo, MD> ;Journal of The European Academy of Dermatology and Venereology. 2016 Aug 09
• 31 citations
  A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
  April W. Armstrong, Michael Bukhalo, Andrew Blauvelt> ;American Journal of Clinical Dermatology. 2016 Jul 19
• 48 citations
  Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psorias...
  Mark Lebwohl, Stephen K. Tyring, Michael Bukhalo, Javier Alonso-Llamazares, Martin Olesen, David Lowson, Paul S. Yamauchi> ;The Journal of Clinical and Aesthetic Dermatology. 2016 Feb 1
• Red, scaly lesion on the upper eyelid.
  Jeffrey S. Altman, Danielle G. Tonelli, Michael Bukhalo> ;American Family Physician. 2007 Nov 15
• 8 citations
  Leukocytoclastic vasculitis induced by use of glyburide: a case of possible cross-reaction of a sulfonamide and a sulfonylurea.
  Michael Bukhalo, Nathalie C. Zeitouni, Richard T. Cheney> ;Cutis. 2003 Mar 1
• Join now to see all

Journal Articles

• Clinical Study Results of Desoximetasone Spray, 025% in Moderate to Severe Psoriasis  
  Kircik L, Lebwohl M, Del Rosso J, Bagel J, Gold L, Weiss J, Journal of Drugs in Dermatology, 1/1/2013
• Calcipotriene Plus Betamethasone Dipropionate Topical Suspension for the Treatment of Mild to Moderate Psoriasis Vulgaris on the body: A Randomized, Double-blind, Vehi...  
  Menter A, Gold L, Bukhalo M, Grekin S, Kempers S, Boyce B, Ganslandt C, Villumsen J, Lenwohl M, Journal of Drugs in Dermatology, 1/1/2013
• Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratosis  
  Bukhalo M, The Journal of Clinical and Aesthetic Dermatology, 1/1/2009
• Photo Quiz: Red, Scaly Lesion on the Upper Eyelid  
  Altman J, Tonelli D, Bukhalo M, American Family Physician, 1/15/2007
• Role of clinical examination is screening for blunt cervical spine injury  
  Gonzales RP, Fried PO, Bukhalo M, Holevar MR, Journal of American College of Surgeons, 1/1/1999
• Join now to see all

Abstracts/Posters

• A Novel Aerosol Foam Formulation of Calcipotriene (Cal) 0.005% Plus Betamethasone Dipropionate (BD) 0.064% is More Efficacious Than Cal and BD Foam Alone in Treating P...
  Lebwohl M, Tyring S, Bukhalo M, Alonso-Llamazares J, Oleses M, Lowson D, Yamauchi P, 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA, 1/20/2015
• A Phase 2 Study of Photodynamic Therapy (PDT) with Aminolevulinic Acid HCI (ALA) 20% Topical Solution + Blue Light vs ALA Topical Solution Vehicle + Blue Light Using S...
  Pariser D, McConnehey D, Matheson R, Kempers S, Guenthner S, Bukhalo M, 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL, 1/1/2013
• Randomized, Parellel-Group, Double-Blind, Vehicle-Controlled, Multicenter Phase 3 Study of the Efficacy and Safety of PEP005 (ingenol mebutate) Gel, 0.015% in Patients...
  Lebwohl M, Melgaard A, Xu Z, 22nd World Congress of Dermatology, Seoul, Korea, 1/24/2011
• Multicenter, Randomized,Parallel-Group, Double-Blind, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of PEP005 (ingenol) Gel 0.05% in Patients W...
  Anderson L, Melgaard A, Xu Z, 22nd World Congress of Dermatology, Seoul, Korea, 1/24/2011
• Join now to see all

Lectures

• A Novel Aerosol Foam Formulation of Calcipotriene (Cal) 0.005% Plus Betamethasone Dipropionate (BD) 0.064% is More Efficacious Than Cal and BD Foam Alone in Treating P... 
  Kaua'I, HI - 1/1/2015
• Use of Light Sources for Acne Therapy 
  St. Thomas, VI - 1/1/2009
• New Trends in Acne Therapy 
  San Antonio, TX - 1/1/2006
• LCV induced by Glyburide 
  Washington, DC - 1/1/2001
• Herpes simplex neonatorum presenting in a zosteriform distribution 
  San Francisco, CA - 1/1/1997
• Join now to see all